Controversy and progress in Alzheimer’s disease — FDA approval of aducanumab

New England Journal of Medicine

28 July 2021 - The FDA’s accelerated approval of aducanumab represents a landmark moment, though the drug’s road to the clinic has been rocky and contentious. 

The hope is that despite its limitations, this first-in-class drug will open the door to more efficacious therapies.

Read New England Journal of Medicine Perspective

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation